114 related articles for article (PubMed ID: 23419368)
21. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
[TBL] [Abstract][Full Text] [Related]
22. Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN-α in patients with relapsing-remitting multiple sclerosis.
Deckx N; Willekens B; Wens I; Eijnde BO; Goossens H; Van Damme P; Berneman ZN; Cools N
Innate Immun; 2016 May; 22(4):266-73. PubMed ID: 27036414
[TBL] [Abstract][Full Text] [Related]
23. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis.
Michel L; Berthelot L; Pettré S; Wiertlewski S; Lefrère F; Braudeau C; Brouard S; Soulillou JP; Laplaud DA
J Clin Invest; 2008 Oct; 118(10):3411-9. PubMed ID: 18769633
[TBL] [Abstract][Full Text] [Related]
24. Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset.
Puthenparampil M; Zito A; Pantano G; Federle L; Stropparo E; Miante S; De Silvestro G; Plebani M; Gallo P
Mult Scler; 2019 Jun; 25(7):918-926. PubMed ID: 29882478
[TBL] [Abstract][Full Text] [Related]
25. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
26. Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing-remitting multiple sclerosis.
Xu L; Xu Z; Xu M
Clin Exp Immunol; 2009 Oct; 158(1):26-30. PubMed ID: 19737227
[TBL] [Abstract][Full Text] [Related]
27. Immune regulatory effects of high dose vitamin D
Muris AH; Smolders J; Rolf L; Thewissen M; Hupperts R; Damoiseaux J;
J Neuroimmunol; 2016 Nov; 300():47-56. PubMed ID: 27806875
[TBL] [Abstract][Full Text] [Related]
28. Multiple sclerosis: Vitamin D deficiency leads to excessive B-cell responses in multiple sclerosis.
Fyfe I
Nat Rev Neurol; 2016 May; 12(5):252. PubMed ID: 27063105
[No Abstract] [Full Text] [Related]
29. Nanocurcumin improves regulatory T-cell frequency and function in patients with multiple sclerosis.
Dolati S; Babaloo Z; Ayromlou H; Ahmadi M; Rikhtegar R; Rostamzadeh D; Roshangar L; Nouri M; Mehdizadeh A; Younesi V; Yousefi M
J Neuroimmunol; 2019 Feb; 327():15-21. PubMed ID: 30683426
[TBL] [Abstract][Full Text] [Related]
30. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Axtell RC; de Jong BA; Boniface K; van der Voort LF; Bhat R; De Sarno P; Naves R; Han M; Zhong F; Castellanos JG; Mair R; Christakos A; Kolkowitz I; Katz L; Killestein J; Polman CH; de Waal Malefyt R; Steinman L; Raman C
Nat Med; 2010 Apr; 16(4):406-12. PubMed ID: 20348925
[TBL] [Abstract][Full Text] [Related]
31. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy.
Saresella M; Marventano I; Longhi R; Lissoni F; Trabattoni D; Mendozzi L; Caputo D; Clerici M
FASEB J; 2008 Oct; 22(10):3500-8. PubMed ID: 18587005
[TBL] [Abstract][Full Text] [Related]
32. Pregnancy-induced fluctuations in functional T-cell subsets in multiple sclerosis patients.
Neuteboom RF; Verbraak E; Wierenga-Wolf AF; van Meurs M; Steegers EA; de Groot CJ; Laman JD; Hintzen RQ
Mult Scler; 2010 Sep; 16(9):1073-8. PubMed ID: 20610493
[TBL] [Abstract][Full Text] [Related]
33. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.
Racke MK; Lovett-Racke AE
J Immunol; 2011 Feb; 186(4):1887-90. PubMed ID: 21289312
[TBL] [Abstract][Full Text] [Related]
34. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
de Andrés C; Aristimuño C; de Las Heras V; Martínez-Ginés ML; Bartolomé M; Arroyo R; Navarro J; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
J Neuroimmunol; 2007 Jan; 182(1-2):204-11. PubMed ID: 17157927
[TBL] [Abstract][Full Text] [Related]
35. Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
Sisay S; Lopez-Lozano L; Mickunas M; Quiroga-Fernández A; Palace J; Warnes G; Alvarez-Lafuente R; Dua P; Meier UC
J Neuroimmunol; 2017 May; 306():40-45. PubMed ID: 28385186
[TBL] [Abstract][Full Text] [Related]
36. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
[TBL] [Abstract][Full Text] [Related]
37. Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms.
Duszczyszyn DA; Beck JD; Antel J; Bar-Or A; Lapierre Y; Gadag V; Haegert DG
Clin Exp Immunol; 2006 Feb; 143(2):305-13. PubMed ID: 16412055
[TBL] [Abstract][Full Text] [Related]
38. Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation.
Arruda LCM; de Azevedo JTC; de Oliveira GLV; Scortegagna GT; Rodrigues ES; Palma PVB; Brum DG; Guerreiro CT; Marques VD; Barreira AA; Covas DT; Simões BP; Voltarelli JC; Oliveira MC; Malmegrim KCR
Clin Immunol; 2016 Aug; 169():47-57. PubMed ID: 27318116
[TBL] [Abstract][Full Text] [Related]
39. Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients.
Matko S; Akgün K; Tonn T; Ziemssen T; Odendahl M
Mult Scler Relat Disord; 2020 Feb; 38():101859. PubMed ID: 31855843
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
Skrzipek S; Vogelgesang A; Bröker BM; Dressel A
Mult Scler; 2012 May; 18(5):674-8. PubMed ID: 22025329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
